Zacks: Brokerages Expect Diffusion Pharmaceuticals Inc (DFFN) to Post -$0.90 Earnings Per Share

Equities research analysts expect Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) to post earnings per share of ($0.90) for the current quarter, according to Zacks. Zero analysts have issued estimates for Diffusion Pharmaceuticals’ earnings. The firm is expected to issue its next quarterly earnings results on Tuesday, April 2nd.

According to Zacks, analysts expect that Diffusion Pharmaceuticals will report full year earnings of ($6.30) per share for the current year. For the next year, analysts expect that the business will post earnings of ($3.60) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Diffusion Pharmaceuticals.

A number of equities research analysts have weighed in on the stock. ValuEngine lowered shares of Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 2nd. HC Wainwright set a $15.00 target price on shares of Diffusion Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, November 15th.

An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned about 0.95% of Diffusion Pharmaceuticals at the end of the most recent reporting period.

DFFN traded down $2.00 during trading on Friday, reaching $5.00. 1,833,043 shares of the company’s stock were exchanged, compared to its average volume of 160,299. Diffusion Pharmaceuticals has a one year low of $1.83 and a one year high of $11.10. The firm has a market capitalization of $10.37 million, a price-to-earnings ratio of -0.29 and a beta of -0.12.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Recommended Story: Stop Order

Get a free copy of the Zacks research report on Diffusion Pharmaceuticals (DFFN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit